BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26202380)

  • 1. Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk.
    Murao T; Shiotani A; Fujita Y; Yamanaka Y; Kamada T; Manabe N; Hata J; Nishio K; Haruma K
    J Gastroenterol Hepatol; 2016 Jan; 31(1):99-106. PubMed ID: 26202380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy.
    Goda K; Murao T; Handa Y; Katsumata R; Fukushima S; Nakato R; Osawa M; Ishii M; Fujita M; Handa O; Matsumoto H; Fujita Y; Nishio K; Wallace TM; Gomez-Esquivel R; Berzosa M; Wolfsen HC; Wallace MB; Umegaki E; Shiotani A
    Esophagus; 2021 Apr; 18(2):306-314. PubMed ID: 32728973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
    Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
    Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
    Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
    Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of endoscopic brushing and magnified endoscopy with narrow band imaging (ME-NBI) to detect intestinal phenotype in columnar-lined esophagus.
    Murao T; Shiotani A; Yamanaka Y; Kimura Y; Tsutsui H; Matsumoto H; Kamada T; Manabe N; Hata J; Haruma K
    J Gastroenterol; 2012 Oct; 47(10):1108-14. PubMed ID: 22576025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk.
    Dura P; van Veen EM; Salomon J; te Morsche RH; Roelofs HM; Kristinsson JO; Wobbes T; Witteman BJ; Tan AC; Drenth JP; Peters WH
    Int J Cancer; 2013 Oct; 133(7):1751-5. PubMed ID: 23504527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NcoI TNF-β gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; van Zoest KP; Moons LM; Hansen B; Pot RG; Siersema PD; Kusters JG; Kuipers EJ
    Scand J Gastroenterol; 2012 Apr; 47(4):378-86. PubMed ID: 22243485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma.
    Murphy SJ; Hughes AE; Patterson CC; Anderson LA; Watson RG; Johnston BT; Comber H; McGuigan J; Reynolds JV; Murray LJ
    Carcinogenesis; 2007 Jun; 28(6):1323-8. PubMed ID: 17277236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Barrett's esophagus in relatives by endoscopic screening.
    Chak A; Faulx A; Kinnard M; Brock W; Willis J; Wiesner GL; Parrado AR; Goddard KA
    Am J Gastroenterol; 2004 Nov; 99(11):2107-14. PubMed ID: 15554988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
    Smith E; De Young NJ; Pavey SJ; Hayward NK; Nancarrow DJ; Whiteman DC; Smithers BM; Ruszkiewicz AR; Clouston AD; Gotley DC; Devitt PG; Jamieson GG; Drew PA
    Mol Cancer; 2008 Oct; 7():75. PubMed ID: 18831746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myo9B is associated with an increased risk of Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; Van Zoest KP; Moons LM; Pot RG; Siersema PD; Kuipers EJ; Kusters JG
    Scand J Gastroenterol; 2012 Dec; 47(12):1422-8. PubMed ID: 22954106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma.
    Xu E; Gu J; Hawk ET; Wang KK; Lai M; Huang M; Ajani J; Wu X
    Carcinogenesis; 2013 Dec; 34(12):2750-6. PubMed ID: 23996928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma.
    Luebeck EG; Curtius K; Hazelton WD; Maden S; Yu M; Thota PN; Patil DT; Chak A; Willis JE; Grady WM
    Clin Epigenetics; 2017; 9():113. PubMed ID: 29046735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.